Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer  by Gonçalves, Pedro & Martel, Fátima
RR
c
P
a
b
a
K
B
B
C
M
S
B
d
t
o
C
w
p
t
s
s
D
o
c
b
(
2
lPorto Biomed. J. 2016;1(3):83–91
Porto  Biomedical  Journal
ht tp : / / www.por tobiomedica l journa l .com/
eview  article
egulation  of  colonic  epithelial  butyrate  transport:  Focus  on
olorectal  cancer
edro  Gonc¸ alvesa,  Fátima  Martelb,∗
Innate Immunity Unit, Institut Pasteur, and the Institut National de la Santé et de la Recherche Médicale (INSERM) U668, Paris, France
Department of Biochemistry, Faculty of Medicine, and Institute for Research and Innovation in Health Sciences, University of Porto, Porto, Portugal
 r  t i  c  l  e  i  n  f  o
eywords:
CRP
utyrate
olorectal cancer
CT1
MCT1
a  b  s  t  r  a  c  t
Colorectal  cancer  (CRC)  is one  of  the most  common  solid  tumors  worldwide.  Consumption  of  dietary
ﬁber  is  associated  with  a low  risk  of  developing  CRC.  The  fermentation  of  the  dietary  ﬁber by intestinal
microﬂora  results  in  production  of butyrate  (BT).  This  short-chain  fatty  acid is  an  important  metabolic
substrate  in normal  colonic  epithelial  cells  and has  important  homeostatic  functions  at the  colonic  level.
Because  the  cellular  effects  of  BT  (e.g. inhibition  of histone  deacetylases)  are  dependent  on  its  intracellu-
lar  concentration,  knowledge  on  the  mechanisms  involved  in  BT membrane  transport  and  its  regulation
seems  particularly  relevant.  In this  review,  we  will  present  the  carrier-mediated  mechanisms  involved
in  BT membrane  transport  at the  colonic  epithelial  level and  their  regulation,  with  an  emphasis  on  CRC.
Several  xenobiotics  known  to modulate  the  risk  for developing  CRC  are  able  to interfere  with  BT transport
at  the  intestinal  level.  Thus,  interference  with  BT transport  certainly  contributes  to  the  anticarcinogenic
or  procarcinogenic  effect  of these  compounds  and  these  compounds  may  interfere  with  the anticarcino-
genic  effect  of  BT. Finally,  we  suggest  that differences  in  BT  transport  between  normal  colonocytes  and
tumoral  cells  contribute  to the  “BT  paradox”  (the  apparent  opposing  effect  of  BT  in  CRC  cells  and  normal
colonocytes).
© 2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
S.L.U.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/utyrate and colorectal cancer
Cancer is the second leading cause of death, after cardiovascular
iseases, in occidental countries1. Colorectal cancer (CRC) is one of
he most common malignancies and cause of cancer death in devel-
ped countries,2 including United States3 and Europe.4 In Europe,
RC is the third most common type of cancer in both men  and
omen and the second leading cause of cancer related-death.2 The
revalence of CRC has been steadily increasing over the last cen-
ury, possibly as a result of industrialization and changes in life
tyle/environmental/dietary factors.2
Both epidemiological and experimental animal studies have
hown that dietary ﬁber possesses a protective role in CRC.5,6
ietary ﬁber exerts a protective role against CRC through a variety
f mechanisms, including reduced concentrations of intestinal car-
inogens owing to increased stool mass, decreased transit time, and
acterial fermentation of resistant starch to short-chain fatty acids
SCFAs: acetate, propionate and butyrate) in the colon.6,7 Among
∗ Corresponding author.
E-mail address: fmartel@med.up.pt (F. Martel).
http://dx.doi.org/10.1016/j.pbj.2016.04.004
444-8664/© 2016 PBJ-Associac¸a˜o Porto Biomedical/Porto Biomedical Society. Publishe
icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).licenses/by-nc-nd/4.0/).
SCFA, butyrate (BT) plays a key role in colonic epithelium home-
ostasis, by having multiple regulatory roles at that level, namely: (1)
it is the main energy source for colonocytes; (2) it promotes growth
and proliferation of normal colonic epithelial cells; (3) it inhibits
colon carcinogenesis; (4) it inhibits colon inﬂammation and oxida-
tive stress; (5) it improves the colonic defense barrier function;
(6) it stimulates ﬂuid and electrolyte absorption; (7) it stimulates
mucus secretion and increases vascular ﬂow and motility; and (8)
it reduces visceral perception, intestinal discomfort, and pain.8,9
Several lines of evidence support an important role of BT in
the prevention/inhibition of colon carcinogenesis.10,11 In vitro, BT
suppresses growth of cancer cells, inducing differentiation and
apoptosis and inhibiting cell proliferation.12,13 Also, several well-
designed animal models have demonstrated a protective effect of
BT on colorectal carcinogenesis.14–19 Moreover, there is an inverse
relationship between the levels of BT in the human colon and the
incidence of CRC,20 and an increased incidence of tumors in the
distal colon, where the concentration of BT is lower, suggesting an
inverse relationship between BT and CRC.21
The molecular mechanism by which BT inhibits colon car-
cinogenesis seems to involve various effects on gene expression,
which are mainly attributed to its capacity to act as an histone
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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eacetylases (HDAC) inhibitor, leading to hyperacetylation of
istones.22,23 HDACs can regulate the expression of a large number
f genes by direct interaction with transcription factors such as p53,
etinoblastoma protein, Stat3, NF-kB and estrogen receptors8 and
istone deacetylase inhibitors (HDACi) are critical epigenetic regu-
ators and a new class of anticancer agents.24 It is likely that BT has
lso some other intracellular targets, including DNA methylation,25
istone methylation,26 hyperacetylation of nonhistone proteins,27
nhibition of histone phosphorylation,28 regulation of expression
f micro-RNAs (miRNA)29,30 and modulation of intracellular kinase
ignaling.31–33
More recently, BT was demonstrated to elicit cellular uptake-
ndependent biologic effects on colonic epithelial cells.34 Indeed,
T was found to be a physiologic agonist of GPR109A, a G-protein-
oupled receptor which is abundantly expressed in the apical
embrane of mouse and human colonic epithelial cells.34,35 SCFAs
ere also reported to be GPR41 and GPR43 ligands.36–38 GPR109A
nd GPR43 appear to act as a colonic tumor suppressors and also
o be involved in the anti-inﬂammatory effect of SCFA.35,36,39,40
ntestinal transport of BT
The most important molecular mechanisms involved in the
nticarcinogenic effect of BT are dependent on its intracellular con-
entration (because HDAC expression is overregulated,41,42 while
T membrane receptors (GPR109A and GPR43) are silenced or
ownregulated in CRC34,38). So, knowledge on the mechanisms
nvolved in its membrane transport is relevant to both its physi-
logical and pharmacological beneﬁts. Also, changes in transporter
xpression or function will have an obvious impact on the effect
f BT, and therefore, knowledge on the regulation of its membrane
ransport seems particularly important.
BT is a weak acid (pKa = 4.8) and more than 90% exist in the ion-
zed form under physiological conditions in the colon (pH 5.5–6.7),
hus requiring a transporter for absorption.43,44 BT is preferen-
ially absorbed in the proximal part of colon where the highest
uminal concentration occurs.45–47 Several different mechanisms
or BT uptake across the apical membrane of colonocytes have
een proposed, including simple diffusion of the undissociated
orm (in the distal colon),43,44 counter-transport with bicarbon-
te (BT/HCO3− exchanger)48,49 and transport by monocarboxylate
ransporters.50,51 The two major monocarboxylate transporters
dentiﬁed for BT absorption across the luminal membranes of
olonocytes are the proton-coupled monocarboxylate transporter
 (MCT1) and the sodium-coupled monocarboxylate transporter 1
SMCT1).50–52 These will be next described.
onocarboxylate transporter 1 (MCT1)
The monocarboxylate transporter (MCT) family is composed
y 14 members encoded by the SLC16 gene family.53 The MCT1
SLC16A1) gene was cloned in 199454 and the structural gene orga-
ization as well as isolation and characterization of the SLC16A1
romoter were later described.55 MCT1 is composed by 500 amino
cids, is well conserved and is ubiquitously expressed in almost
very tissue.56 MCT1 protein levels vary along the human digestive
ract: the expression of MCT1 is very low in the small intes-
ine but it increases in the colon with maximal levels in the
istal segment, being conﬁned to the upper regions of colonic
rypts.57,58 The precise subcellular localization of MCT1 remains
ontroversial: a predominant basolateral57,59,60 or apical mem-
rane localization58,61 or its presence in both cell membranes62
as been described.
MCT1 translocates a proton through the plasma membrane
ogether with a molecule of BT.63 Physiologically, MCT1 is probablyomed. J. 2016;1(3):83–91
more active in the proximal colon, because its Km for BT is about
2.4–2.8 mM,  and there is a higher concentration of BT (in the mM
range after digestion of dietary ﬁber) and the luminal pH is lower
in this region.21
MCT1 transports a variety of natural substrates including mono-
carboxylates (e.g. BT) and ketoacids.53 Moreover, numerous drugs
containing a carboxyl group in their chemical structure and/or
weak organic acids may  be potential substrates for MCT1. Exam-
ples of such drugs are salicylic acid, nonsteroidal anti-inﬂammatory
drugs (NSAIDS), benzoic acid, nicotinic acid, lonidamine, choles-
terol synthesis inhibitors and some -lactam antibiotics.64–66
MCT1 regulation
Transporter regulation includes transcriptional (activators and
repressors), post-transcriptional (splice variants), chromosomal
(epigenetic modiﬁcations), translational (mRNA stability) and post-
translational (alteration of protein) modiﬁcations. MCT1 is known
to be regulated at the transcriptional and post-transcriptional level,
and at the level of transporter activity.
MCT1 is known to be regulated at various points during
gene expression (transcriptional regulation). SLC16A1 promoter
has putative binding site sequences for the transcription factors
upstream stimulatory factor (USF) 1 and 2 (MCT1 repressors),67
NF-B (involved in BT-induced MCT1 upregulation),68 activated
protein 1 and 2 (AP1 and AP2) and stimulating protein-1
(Sp1).55 Also, the co-activators peroxisome proliferator-activated
receptor gamma  coactivator 1 alpha (PGC-1)69 and peroxi-
some proliferator-activated receptor alpha (PPAR)70,71 upreg-
ulate MCT1. Hormone regulation has also been described.
Somatostatin,72 leptin,73 thyroid-stimulating hormone74 and
testosterone75 induce MCT1 expression.
MCT1 is also under post-transcriptional regulation by microR-
NAs. The MCT1 untranslated region is a target for three microRNAs
(miR-29a, miR-29b, and miR-124), and recently, miR-29a and miR-
29b have been described to silence MCT1 expression.76
MCT1 activity is modulated by several compounds, described as
classic inhibitors of MCT1: (1) bulky or aromatic monocarboxylates
like -cyano-4-hydroxycinnamate; (2) inhibitors of anion trans-
port such as 5-nitro-2-(3-phenylpropylamino)benzoate; (3) thiol
reagents, such as p-chloromercuribenzene sulphonate (pCMBS),
and amino reagents.53
MCT1 expression is downregulated in the inﬂamed mucosa of
inﬂammatory bowel disease patients, in animal models of inﬂam-
mation, and in response to the proinﬂammatory cytokines tumor
necrosis factor- (TNF-)  and interferon- (IFN-).77 Interest-
ingly, inﬂiximab (an anti-TNF- monoclonal antibody) markedly
increased MCT1 mRNA levels in the inﬂamed colon of Crohn’s dis-
ease patients.57 The reduction in the cellular uptake of BT occurring
during inﬂammation may  contribute to the fact that inﬂammatory
bowel disease is associated with an elevated risk of CRC.77,78
Physical activity, known to reduce CRC risk,79 increases MCT1
protein expression and activity in muscle.80,81 Because MCT1 is
substrate-induced by lactate,82 the increased blood lactate levels
found after physical activity can affect MCT1 levels in colon.
MCT1 is associated with a plasma accessory protein, the mem-
brane glycoprotein CD147 (also known as basigin, EMMPRIN,
OX-47 or HT7), and this ancillary protein is known to be involved
in regulating MCT1 localization and activity.83
MCT1 is also functionally coupled to proteins involved in
acid/base regulation. Indeed, carbonic anhydrase,84 Na+/HCO3−
cotransporter and Na+/H+ exchangers85 enhance MCT1 transport
activity.
Several nutrients and xenobiotics present in the diet were
also found to affect MCT1 expression and activity. Intestinal
MCT1 gene expression is decreased by the polyphenols EGCG,
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yricetin, and catechin,12 by caffeine, tetrahydrocannabinol and
DMA  (ecstasy),86 by high-protein diets (linked to NH3- and
NF--mediated signaling)87 and by fasting.88 In contrast it is
ncreased by chrysin.86 The expression of MCT1 as well as its
bundance in the apical surface of the colonic mucosal sections
ncreased in pectin-fed rats compared with rats on ﬁber-free
iet.62,89 Moreover, substrates of MCT1 such as BT increased MCT1
rotein expression in colon68,90,91 and its apical localization.92
ecently, substrate (e.g. BT)-induced enhancement of MCT1 sur-
ace expression and function was found to be mediated by a
ovel nutrient sensing mechanism involving GPR109A as a SCFA
ensor.89 MCT1 activity is also modulated by several exoge-
ous compounds. Acutely, MCT1 is inhibited by NSAIDs (e.g.
cetylsalicylic acid and indomethacin),86,93,94 some phytochemi-
als (e.g. resveratrol, quercetin, myricetin, chrysin, (−)-epicatechin
nd (−)-epigallocatechin gallate),12,94–96 xanthines (caffeine and
heophylline) and acetaldehyde.86 Chronically, MCT1 activity is
nhibited by tetrahydrocannabinol, MDMA,86 the bile salt chen-
deoxycholic acid,97 enteropathogenic Escherichia coli,98 IFN- and
NF-77 and is increased by caffeine (an effect not related to
hanges in the expression level of MCT1, as this agent decreased
his parameter; see above),86 some phytochemicals (e.g. quercetin,
GCG, rutin, chrysin, myricetin and catechin)12 and some mineral
aters (Melgac¸ o® and Vidago®).99 Of note, Lactobacillus acidophilus
ounteracts E. coli-induced inhibition of BT uptake in intestinal
pithelial cells.100 In conclusion, numerous nutrients and xenobi-
tics can modulate MCT1 expression and activity, and competition
or the same transport pathway between BT and these compounds
an cause a signiﬁcant change in BT absorption.
CT1 and CRC
The ﬁrst report on MCT1 protein expression in human tumor
amples described a decrease in MCT1 expression in colonic tran-
ition from normality to malignancy.61,101 Evidence for MCT1
ownregulation was later observed also in other cancer types.61,102
he loss or silencing of MCT1 has been demonstrated to corre-
ate with: (a) transition from normality to malignancy in colonic
pithelium,61 (b) dysregulation of BT-responsive genes involved in
ifferentiation and apoptosis101,103 and (c) an important metabolic
witch from BT -oxidation to glycolysis. In relation to this last
oint, it should be noted that BT is the main energy source for
olonocytes, accounting to about 70% of total energy utilization.104
owever, CRC cells show a reduction in BT uptake as a result of
educed MCT1 (and SMCT1; see below) expression,104,105 asso-
iated with an increase in the rate of glucose uptake (via an
pregulation of facilitative glucose transporters (e.g. GLUT1))106
nd glycolytic oxidation (via an increase in the expression levels
nd activity of glycolytic enzymes).104,107,108
Although MCT1 expression decreases during colonic transi-
ion from normality to malignancy, being downregulated in the
arly stages of carcinogenesis,61 a later upregulation of MCT1
n advanced metastatic CRC tumors has been described.109,110
olid tumors are usually exposed to low oxygen environments.
nterestingly enough, although MCT1 expression is not HIF-1
nduced,111 CD147, the accessory protein that MCT1 requires
n order to function, is upregulated by HIF-1 under hypoxic
icroenvironment.112 In advanced CRC tumors, cells are highly
lycolytic and convert the majority of glucose into lactate and
hus cells must efﬁciently export lactate, in order to maintain a
ermissive intracellular pH, high glycolytic rates and ATP levels.113CTs are bidirectional transporters114 and powerful regulators of
ntracellular pH by extruding lactate together with a proton.113
ccordingly, MCT1 inhibition decreases intracellular pH, resulting
n tumoral cell death.108,115,116 So, upregulation of some MCTomed. J. 2016;1(3):83–91 85
isoforms may  occur as a means of exporting lactate. In this con-
text, lactate transporters (MCTs) are currently seen as potential
therapeutic targets in cancer treatment, with promising results
having been obtained.117–119 However, systemic delivery of MCTs
(and more speciﬁcally, MCT1) inhibitors could affect almost every
organ of the body, with the most drastic effects on cardiac and
skeletal muscle.120 Also, in CRC cells, both MCT1 and MCT4 appear
to play a pivotal role in lactate transport and tumor survival and
development.121,122 However, no speciﬁc MCT4 small molecule
inhibitor has been identiﬁed so far.123 BT was previously approved
for clinical use in CRC treatment,124 because BT is a substrate of
both MCT1 and MCT4 and is well metabolized, having no side
effects.120 Because BT competes with lactate for MCT1 and is a
HDACi, it is a good compound to test in the context of inhibition
of lactate release in CRC.125 So, although the anticarcinogenic
effect of BT is believed to result from HDAC inhibition,23 it is also
interesting to speculate that MCT-mediated BT uptake may  result
in a decrease in the intracellular pH, originating tumoral cell death.
Sodium-coupled monocarboxylate transporter 1 (SMCT1)
SMCT1 is a member of the sodium solute symporter fam-
ily (SLC5), ﬁrst cloned in 2002.126 This transporter is encoded
by the SLC5A8 gene127 and the SLC5A8 gene promoter has
also been characterized.128 SLC5A8 encodes a protein with 610
amino acids,129 having a restricted distribution (primarily kidney
and intestine).130 At the intestinal level, SLC5A8 is abundantly
expressed in the apical membrane of the ileum and colon,131,132
and its levels are highest in distal colon, followed by proximal
colon and ileum.78 SLC5A8 transports a variety of monocarboxy-
lates such as lactate, pyruvate and -hydroxybutyrate (GHB),132,133
ketone bodies,134 nicotinate structural analogs,135 pyroglutamate
(amino acid derivative)136 and benzoate and its derivatives (sali-
cylate and 5-aminosalicylate).135 SLC5A8 has been characterized
as a Na+-coupled BT transporter137,138 being thus also referred
as sodium-coupled monocarboxylate transporter 1 (SMCT1).130
Recent studies showed that SMCT1 is also present in normal human
intestinal cell lines78,94; however, no studies have characterized
SMCT1 function in the native human intestine. Because SMCT1 has
a low Km (50 M)  for BT139 and is more expressed in distal colon,78
SMCT1 is probably physiologically more important in the distal
colon (where the concentrations of BT are lower).21
SMCT1 regulation
Knowledge on the regulation of SMCT1 at the intestinal
level is very scarce. SMCT1 has been found to be inhibited by
some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and
indomethacin94), phytochemicals (resveratrol and quercetin94),
TNF-,76 oxidative stress,140 chenodeoxycholic acid97 and by the
absence of gut commensal bacteria.141 On the contrary, SMCT1
was found to be stimulated by some other NSAIDs (diclofenac,
meclofenamate and sulindac142), by activin A143 and by the pro-
biotic Lactobacillus plantarum.76
Obesity and diabetes are risk factors for developing CRC143,144
and it is interesting to verify that ob/ob mice (an animal
model of obesity) show a decrease in SMCT1 protein intestinal
levels.145 Inﬂammatory bowel disease is also associated with an
increased risk for CRC,9 and SMCT1 is also downregulated during
inﬂammation.78
SMCT1 and CRCStudies have shown that SMCT1 expression is frequently
silenced in aberrant crypt foci (the earliest detectable morpho-
logic abnormality of the colonic epithelium), colon adenomas,
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olon cancers and colon cancer cell lines, suggesting that SMCT1
ilencing is an early event in colon tumorigenesis.127,130 Inter-
stingly, CRC patients often have allelic loss of chromosome 12q,
hich contains the SLC5A8 gene.146,147 SMCT1 is also silenced in
ancers of the thyroid, head and neck, breast, stomach, prostate,
ancreas and blood.130,148,149 SMCT1 is silenced by aberrant DNA
ypermethylation.148,150 Therefore, SMCT1 was proposed to func-
ion as a tumor suppressor, the ability of this transporter to mediate
he entry of BT into colonocytes underlying its potential tumor
uppressor function,52,127,130 and combination of upregulation of
atrix metalloproteinases-7 and SMCT1 downregulation is an opti-
al  biomarker for identifying CRC cases.151 Also, SMCT1 activity is
ositively correlated with CRC remission and patient survival.152
owever, Smct1-null mice do not reveal a higher incidence of
umors in the colon under optimal dietary ﬁber conditions, pos-
ibly because BT is transported by Mct1 under these conditions.
ut, under low-ﬁber dietary conditions, the incidence of CRC is
uch higher in Smct1-null mice, possibly because, being the lumi-
al concentrations of BT much lower, it is not transported by
ct1 and Smct1 becomes the most important BT transporter.153,154
ecently, ectopic expression of SMCT1 in cancer cells (that have
MCT1 silenced) was found to induce the translocation of the anti-
poptotic protein survivin to plasma membrane and cell cycle
rrest, apoptosis and enhancement in chemosensitivity, indepen-
ently of the transport function of SMCT1 and of the histone
cetylation status of the cell.155 So, the tumor-suppressive role of
MCT1 does not depend exclusively on the ability of this trans-
orter to mediate the entry of HDAC inhibitors such was BT and
yruvate into cells.
reast cancer resistance protein (BCRP)
BT cellular pools are not only dependent on the above BT
ptake systems but also depend on efﬂux transporters, capable
f removing BT from the cells. The ATP-binding cassette (ABC)
ransporter superfamily includes membrane proteins that translo-
ate a wide variety of substrates across membranes.156 The human
ntestinal tract expresses high levels of some ABC transporters
e.g. P-glycoprotein (MDR1; encoded by ABCB1), multidrug resis-
ance protein 1 (MRP1; encoded by ABCC1), and the breast cancer
esistance protein (BCRP; encoded by ABCG2)), and these efﬂux
ransporters are believed to be involved in limiting drug absorp-
ion, bioavailability, and toxicity.156 We  recently veriﬁed that BT
s a BCRP substrate. Interestingly, inhibition of BCRP signiﬁcantly
otentiated the inhibitory effect of BT upon cell proliferation.157
CRP and CRC
BCRP mRNA and protein expression are signiﬁcantly down-
egulated in human colorectal adenomas,156 in ApcMin mice (a
ouse model of colon cancer),156 in human CRC tissue and in most
uman cancers,158 suggesting that malignant transformation of the
olonic epithelium in vivo is accompanied by a signiﬁcant down-
egulation of BCRP. Accordingly, we demonstrated that, contrary
o non-tumoral intestinal epithelial cells (IEC-6 cells), Caco-2 cells
a tumoral cell line derived from a colon adenocarcinoma) do not
how BCRP-mediated efﬂux of BT.157 BCRP expression is also dra-
atically reduced in inﬂammatory bowel disease,159–161 which is
nteresting in the context of the relationship between inﬂammatory
owel disease and CRC.156
The mechanisms involved in BCRP downregulation in CRC
ave not been much investigated. BCRP expression depends on
nt/-catenin signaling pathway in colon cancer cell lines162
nd mutations of the -catenin gene are frequently found
n chemically-induced colon tumors in both rat and mouseomed. J. 2016;1(3):83–91
carcinogenesis models163 and in human colon tumors,164 sug-
gesting that inhibition of this signaling pathway may decrease
BCRP expression. Studies also demonstrated that human BCRP
polymorphisms causing a decrease in its activity could inﬂuence
the individual susceptibility to cancer.165,166 Interestingly enough,
BCRP exerts a protective function at the intestinal epithelial level
by limiting the access of dietary mutagens and carcinogens.167,168
So, a decrease in BCRP expression/function may  place an individual
at greater risk of exposure to dietary/environmental carcinogens.
As mentioned above, CRC is associated with a downregulation
of BCRP.158 However, some studies described BCRP overex-
pression in colorectal invasive cancers (i.e., advanced stage of
carcinogenesis),169–171 suggesting that BCRP may  be involved in
cancer progression and metastasis, and some other studies showed
that BCRP is overexpressed in solid tumors.172 Most solid tumors
are exposed to low oxygen environments and BCRP gene transcrip-
tion is activated by binding of HIF-1  to a hypoxia response element
under low oxygen conditions.173 c-Myc overexpression also upreg-
ulates BCRP,174 and pregnane X receptor (also known as the steroid
and xenobiotic sensing nuclear receptor) also contributes to upreg-
ulation of BCRP.175
An important point relates to the fact that BCRP is known to
be overexpressed in cancer cell lines and tumors that are “mul-
tidrug resistant” (MDR).176 The term “multidrug resistance” (MDR)
is used to describe the ability of cells exposed to a single drug to
develop resistance to a broad range of structurally and function-
ally unrelated drugs.177 BCRP is one of the human ABC transporters
implicated in MDR  in cancer chemotherapy.178,179 BCRP recognizes
and transports numerous anticancer drugs including conven-
tional chemotherapeutic and relatively new molecules in clinical
use: 5-ﬂuorouracil, methotrexate, mitoxantrone, anthracyclines,
daunorubicin, doxorubicin, topotecan, diﬂomotecan, irinotecan,
tyrosine kinase inhibitors (e.g. imatinib and geﬁtinib) and nucle-
oside analogs.180–182 Thus, downregulation of BCRP expression
and/or function has been proposed as part of a regimen to improve
cancer therapeutic efﬁcacy. Several speciﬁc inhibitors of BCRP have
been reported, and some are currently undergoing clinical trials or
are available to treat patients.172 BT, by competing with anticancer
agents for BCRP, may  increase their intracellular level, thereby
increasing their cytotoxicity. In agreement with this, a synergistic
effect of the combination of BT with anticancer agents transported
by BCRP has been reported.180–182 So, interaction of BT with BCRP
and with other BCRP substrates/inhibitors will have clinical impli-
cations for CRC therapy.180–183
BT transport and CRC
BT is the main energy source for colonocytes and promotes
growth and proliferation of normal colonic epithelial cells.184,185
However, BT suppresses the growth of cancer cells (inducing dif-
ferentiation and apoptosis and inhibiting cell proliferation).13 This
apparent opposing effect of BT upon growth of normal versus
tumoral colonocytes has been referred to as the “BT paradox”.186
Differences in BT metabolism between normal and tumoral
cells lines, more speciﬁcally the Warburg effect, may contribute to
this “paradox”.186 In normal colonocytes, BT stimulates cell growth
by functioning as an oxidative energy source; it is the primary
fuel of these cells, being metabolized by -oxidation followed
by the tricarboxylic acid (TCA) cycle.102,187 On the contrary, BT is
inefﬁciently metabolized in cancerous colonocytes, since glucose
takes the place of BT as the major energy source (the Warburg
effect), and it accumulates at greater levels inside of nuclei (being
therefore a candidate oncometabolite), with a corresponding
increase in HDAC inhibition.179,186 This results in inhibition of cell
growth (Fig. 1). Interestingly, several studies have shown that high
P. Gonc¸ alves, F. Martel / Porto Biomed. J. 2016;1(3):83–91 87
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Fig. 1. (a) Proposed model of expression and function of BT transporters in normal colonocytes. Transporters such as MCT1 (monocarboxylate transporter 1, gene name
SLC16A1) and SMCT1 (sodium-coupled monocarboxylate transporter 1, gene name SLC5A8) mediate inﬂux of BT at the apical membrane. BT is rapidly metabolized in the
tricarboxylic acid (TCA) cycle. BCRP (gene name ABCG2), an ATP-dependent efﬂux transporter, mediates BT efﬂux at the apical membrane. At the basolateral membrane,
efﬂux  of BT occurs via MCT4 (monocarboxylate transporter 4, gene name SLC16A3). (b) Proposed model of expression and function of BT transporters in tumoral colonocytes.
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bn  tumoral colonocytes, glycolysis becomes the primary energy source, exceeding B
actate. BT, which is now less oxidized, behaves as a histone deacetylase inhibitor p
actate at the apical membrane. Adapted from Refs. 188,194.
oncentrations (5 mM)  of BT induces H3ac acetylation, decreases
ell proliferation and viability and induces cell differentiation also
n non-tumoral intestinal epithelial cell lines.157,179,186,188 This can
e explained by the fact that 1–2 mM corresponds to the oxidative
apacity of these cells.189 Therefore, at concentrations greater
han 2 mM,  BT accumulates and functions as a HDAC inhibitor
lso in normal colonocytes. Altogether, these ﬁndings lead to a
odel whereby BT facilitates the normal turnover of the colonic
pithelium by promoting colonocyte proliferation in the bottom
alf of each crypt, where there is a low concentration of BT, while
ncreasing apoptosis in those cells that exfoliate into the lumen
because of a higher concentration of BT).179,186
Differences in HDACs expression levels between normal and
umoral cells lines also contribute to the “BT paradox”, because
DACs appear to be overexpressed in CRC cells.38,39 The Warburg
ffect appears to be a cause, rather than a consequence of this
echanistic shift in histone acetylation.179,186
Differences in BT transport between normal and tumoral cells
ines also appear to contribute to the “BT paradox”. In normal colon
pithelial cells, BT is taken up by MCT1 and SMCT1 located at the
pical membrane52,94,103 and, being the main energy source for the
olonocytes, it is metabolized.179,186 BT that is not metabolized is
fﬂuxed by BCRP, thus decreasing its intracellular concentration
nd so BT has no effect at HDACs157 (Fig. 1). This is consis-
ent with the fact that in normal colonic tissue, BT does not
nhibit cell proliferation.190–192 As shown above, studies described
CT1 upregulation in advanced metastatic CRC tumors. There-
ore, in tumoral colon epithelial cells, BT is taken up by MCT1
ocated at the apical membrane86,103,109,110 but it is metabolized
nefﬁciently due to the Warburg effect179,186; moreover, it does
ot suffer BCRP-mediated efﬂux.157 So, it accumulates at greater
evels inside of nuclei179,186 thus acting as a HDAC inhibitor,
eading to hyperacetylation of histones and to increased accessi-
ility of transcription factors to DNA promoters,23 thus inducingative energetic metabolism, and cells rapidly convert the majority of glucose into
ing histone acetylation. MCT1 mediates inﬂux of BT and may  also mediate efﬂux of
apoptosis,12,13 inhibiting proliferation and promoting a more dif-
ferentiated phenotype12,186,193 (Fig. 1).
Conclusions
BT is the main energy source for normal colonic epithelial cells
and inhibits colon carcinogenesis. Because the cellular effects of
BT (e.g. inhibition of histone deacetylases) are dependent on its
intracellular concentration, knowledge on intestinal BT transport
mechanisms and its regulation is crucial in the context of the phys-
iological effects of BT and of CRC pathophysiology.
Because several xenobiotics known to modulate the risk for
developing CRC can modulate BT transport, it is plausible that inter-
ference with BT transport contributes to their anticarcinogenic or
procarcinogenic effect and that these compounds may interfere
with the anticarcinogenic effect of BT.
Moreover, differences in MCT1, SMCT1 and BCRP expression
between normal colonocytes and tumoral cells contribute to the
different effects of BT in these cells (‘the BT paradox’). More specif-
ically, BT is transported into normal colonic epithelial cells by both
MCT1 and SMCT1, but its intracellular concentration is kept low
because it is efﬁciently metabolized and efﬂuxed from these cells
by BCRP-mediated transport. In contrast, colonic epithelial tumoral
cells show a decrease in SMCT1 protein expression, and BT is taken
up by these cells through MCT1. In these cells, BT accumulates intra-
cellularly because it is inefﬁciently metabolized (due to the fact
that glucose becomes the primary energy source of these cells) and
because there is a reduction in BCRP expression.Conﬂict of interest
No conﬂicts of interest are declared by the authors.
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